Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This research study investigates the use of a drug, cabergoline, given immediately after
second-trimester abortion or perinatal loss to decrease breast engorgement. Cabergoline is a
medication approved for the symptomatic treatment of pituitary adenomas that result in a
hyperprolactinemic state (a brain tumor that results in milk leakage). The benefit of
stopping milk leakage has also been studied and used in populations who shouldn't breastfeed.
The investigators aim to clarify if cabergoline is effective in preventing breast engorgement
and milk leakage after second-trimester abortions or perinatal loss (stillbirth). Breast
engorgement causes physical pain and emotional distress as lactation is uniquely associated
with parenthood and those undergoing second-trimester abortions are doing so because they
choose not to parent or a previously desired pregnancy is now complicated by anomalies. As
there are no current recommendations for management of this painful engorgement beyond
icepacks and support bras, the investigators aim to validate the use of this pharmacologic
option in this setting.